Eli Lilly added additional late-stage results for retatrutide, reporting top-line outcomes from two Phase 3 obesity studies that include serious type 2 diabetes and cardiovascular complications. The data are positioned to support a BLA filing timeline early next year, as Lilly reiterated retatrutide’s “triple-G” approach. Coverage also highlighted how the additional readouts sharpen comparisons within the incretin agonist landscape, where investors are watching for both weight loss magnitude and longer-term cardiometabolic risk signals. The filing pathway now becomes the near-term catalyst for the next competitive phase in obesity therapeutics.